Cord Blood Transplant for Children and Young Adults with Blood Cancers and Non-Cancerous Disorders
Sponsor: Memorial Sloan Kettering Cancer Center
ClinicalTrials ID:NCT04644016
This study is exploring the use of cord blood transplants in children and young adults with serious blood cancers and other life-threatening blood disorders who do not have a suitable donor for a traditional transplant.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This clinical trial is focused on using cord blood transplants to treat children and young adults with severe blood cancers and non-cancerous blood disorders. The study aims to understand the safety and effectiveness of this treatment in patients who do not have a matched donor for a traditional bone marrow transplant. Cord blood, which is collected from the umbilical cord after birth, is used because it can be a good alternative when a suitable donor is not available.
Eligibility Criteria
Inclusion Criteria
- Children and young adults aged 21 or younger without a suitable donor for a traditional transplant.
- Diagnosed with certain types of blood cancers like acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) at high risk of returning or not responding to treatment.
- Diagnosed with other blood disorders like myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD) that are life-threatening.
- Diagnosed with high-risk non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) that is not in remission.
- Diagnosed with certain inherited metabolic disorders early in the disease, such as Hurler Syndrome or Metachromatic Leukodystrophy.
- Diagnosed with non-cancerous blood disorders like hemoglobinopathies or bone marrow failure syndromes.
- Must have good organ function and be in relatively good health, with specific blood and organ function levels.
- Must meet specific criteria for cord blood transplant, including matching and cell count requirements.
Exclusion Criteria
- Poor overall health or organ function.
- Advanced metabolic disease.
- Active leukemia in the central nervous system.
- Progression of indolent NHL or Hodgkin lymphoma after recent treatment.
- Diagnosed with myelofibrosis or other cancers with significant bone marrow issues.
- Recent autologous stem cell transplant within the last 6 months.
- Previous allogeneic stem cell transplant.
- Active and uncontrolled infections at the time of transplant.
- HIV infection or positive for HTLV-1.
- Pregnant or breastfeeding.
- Unable to provide informed consent or follow the treatment plan.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
